Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEVRO CORPNVRO · Entity 12422 | Director | March 31, 2024 | April 02, 2024 |
| NeuroPace IncNPCE · Entity 5459 | Director | June 19, 2026 | June 22, 2026 |
| Tenon Medical, Inc.TNON · Entity 2063 | Director | May 22, 2023 | May 24, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEVRO CORP
Report date March 31, 2024 · Filed April 02, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 57,500 |
Reported balance
After 2024-03-31 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-03-31 · Grant · Acquired 1,159 · Balance 57,500 F1: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2: Includes 6,754 restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash.
F2: Includes 6,754 restricted stock units.
NeuroPace Inc
Report date June 19, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 599,534 |
Reported balance
After 2026-06-19 transaction · row 1
1 source rowRow 1 · 2026-06-19 · Grant · Acquired 1,467 · Balance 599,534 F1: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees.
Tenon Medical, Inc.
Report date May 22, 2023 · Filed May 24, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,207 |
Reported balance
After 2023-05-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-05-22 · Exercise / conversion · Acquired 6,207 · Balance 6,207 F1: These shares of common stock were issued pursuant to the vesting of Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2032-05-12 | Direct | 12,416 |
Reported balance
Holding disclosure · report date 2023-05-22 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 12,416 F2: The units vest for three years on an annual basis. F3: 18,623 RSUs were initially granted on May 12, 2022. 6,207 RSUs vested as of May 22, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares of common stock were issued pursuant to the vesting of Restricted Stock Units.
F2: The units vest for three years on an annual basis.
F3: 18,623 RSUs were initially granted on May 12, 2022. 6,207 RSUs vested as of May 22, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 19, 2026 Filed Jun 22, 2026 20:33 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 1,467 | $15.63 | $22,929.21 |
DisclosureSEC source: 0001297260-26-000007 · wk-form4_1782160401.xml · nonDerivative · entry 1 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 599,534 F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees. Read SEC document |
| June 05, 2026 Filed Jun 5, 2026 21:10 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantStock Option (Right to Buy) · Derivative | 5,368 | $0.00 Strike: $15.74 | $0.00 |
DisclosureSEC source: 0001297260-26-000005 · wk-form4_1780693848.xml · derivative · entry 2 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,368 Underlying: Common Stock · 5,368 shares Expires 2036-06-04 F2 · derivative.exercise_date: The shares subject to the option shall vest in twelve (12) equal consecutive monthly installments until all of the option shares are fully vested and exercisable, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| June 05, 2026 Filed Jun 5, 2026 21:10 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 2,890 | $0.00 | $0.00 |
DisclosureSEC source: 0001297260-26-000005 · wk-form4_1780693848.xml · nonDerivative · entry 1 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 598,067 F1 · shares: The shares shall vest in twelve (12) equal consecutive monthly installments until all of the shares are fully vested, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| March 20, 2026 Filed Mar 23, 2026 20:41 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 1,826 | $13.00 | $23,738.00 |
DisclosureSEC source: 0001297260-26-000003 · wk-form4_1774298494.xml · nonDerivative · entry 1 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 595,177 F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees. Read SEC document |
| December 19, 2025 Filed Dec 23, 2025 21:15 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 1,431 | $16.59 | $23,740.29 |
DisclosureSEC source: 0001297260-25-000006 · form4-12232025_041217.xml · nonDerivative · entry 1 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 593,351 F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees. Read SEC document |
| September 19, 2025 Filed Sep 22, 2025 23:30 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 2,389 | $9.94 | $23,746.66 |
DisclosureSEC source: 0001297260-25-000004 · form4-09222025_070901.xml · nonDerivative · entry 1 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 591,920 F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees. Read SEC document |
| June 21, 2025 Filed Jun 24, 2025 20:30 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 2,281 | $10.41 | $23,745.21 |
DisclosureSEC source: 0001415889-25-018088 · form4-06242025_040601.xml · nonDerivative · entry 9 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 589,531 F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees. Read SEC document |
| June 06, 2025 Filed Jun 9, 2025 21:25 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantStock Option (right to buy) · Derivative | 8,745 | $0.00 Strike: $13.15 | $0.00 |
DisclosureSEC source: 0001415889-25-016325 · form4-06092025_050603.xml · derivative · entry 1 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,745 Underlying: Common Stock · 8,745 shares Expires 2035-06-05 F1 · derivative.exercise_date: The shares subject to the option shall vest in twelve (12) equal consecutive monthly installments until all of the option shares are fully vested and exercisable, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| March 21, 2025 Filed Jun 24, 2025 20:30 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 1,975 | $12.02 | $23,739.50 |
DisclosureSEC source: 0001415889-25-018088 · form4-06242025_040601.xml · nonDerivative · entry 8 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 587,250 F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees. Read SEC document |
| December 21, 2024 Filed Jun 24, 2025 20:30 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 2,059 | $11.53 | $23,740.27 |
DisclosureSEC source: 0001415889-25-018088 · form4-06242025_040601.xml · nonDerivative · entry 7 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 585,275 F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees. Read SEC document |
| September 30, 2024 Filed Jun 24, 2025 20:30 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 3,407 | $6.97 | $23,746.79 |
DisclosureSEC source: 0001415889-25-018088 · form4-06242025_040601.xml · nonDerivative · entry 6 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 583,216 F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees. Read SEC document |
| June 28, 2024 Filed Jun 24, 2025 20:30 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 3,141 | $7.56 | $23,745.96 |
DisclosureSEC source: 0001415889-25-018088 · form4-06242025_040601.xml · nonDerivative · entry 5 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 579,809 F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 20:16 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantStock Option (Rt to Buy) · Derivative | 17,774 | $0.00 Strike: $6.47 | $0.00 |
DisclosureSEC source: 0001415889-24-016360 · form4-06112024_080646.xml · derivative · entry 1 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,774 Underlying: Common Stock · 17,774 shares Expires 2034-06-06 F1 · derivative.exercise_date: The shares subject to the option shall vest in twelve (12) equal consecutive monthly installments until all of the option shares are fully vested and exercisable. Read SEC document |
| March 31, 2024 Filed Apr 2, 2024 19:04 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 1,159 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000200 · form4.xml · nonDerivative · entry 1 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,500 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 6,754 restricted stock units. Read SEC document |
| March 29, 2024 Filed Jun 24, 2025 20:30 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 1,799 | $13.20 | $23,746.80 |
DisclosureSEC source: 0001415889-25-018088 · form4-06242025_040601.xml · nonDerivative · entry 4 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 576,668 F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees. Read SEC document |
| December 31, 2023 Filed Jan 3, 2024 16:50 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 778 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000004 · form4.xml · nonDerivative · entry 1 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,341 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 6,754 restricted stock units. Read SEC document |
| December 29, 2023 Filed Jun 24, 2025 20:30 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 2,303 | $10.31 | $23,743.93 |
DisclosureSEC source: 0001415889-25-018088 · form4-06242025_040601.xml · nonDerivative · entry 3 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 574,869 F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees. Read SEC document |
| September 30, 2023 Filed Oct 3, 2023 16:56 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 871 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-23-000303 · form4.xml · nonDerivative · entry 1 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,563 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 6,754 restricted stock units. Read SEC document |
| September 29, 2023 Filed Jun 24, 2025 20:30 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 2,440 | $9.73 | $23,741.20 |
DisclosureSEC source: 0001415889-25-018088 · form4-06242025_040601.xml · nonDerivative · entry 2 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 572,566 F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 17:07 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 658 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-23-000196 · form4.xml · nonDerivative · entry 1 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,692 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 6,754 restricted stock units. Read SEC document |
| June 30, 2023 Filed Jun 24, 2025 20:30 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 4,469 | $4.49 | $20,065.81 |
DisclosureSEC source: 0001415889-25-018088 · form4-06242025_040601.xml · nonDerivative · entry 1 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 570,126 F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees. Read SEC document |
| June 07, 2023 Filed Jun 14, 2023 20:59 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantStock Option (Rt to Buy) · Derivative | 27,380 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0001209191-23-037077 · doc4.xml · derivative · entry 1 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,380 Underlying: Common Stock · 27,380 shares Expires 2033-06-06 F1 · derivative.exercise_date: The shares subject to the option shall vest in twelve (12) equal consecutive monthly installments until all of the option shares are fully vested and exercisable. Read SEC document |
| May 25, 2023 Filed May 30, 2023 17:18 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 6,754 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-23-000077 · form4.xml · nonDerivative · entry 1 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,034 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of May 25, 2023 or (ii) the next Annual Meeting following May 25, 2023, subject to the Reporting Person's continued service to the Issuer. F2 · balance_after: Includes 6,754 RSUs. Read SEC document |
| May 22, 2023 Filed May 24, 2023 23:35 UTC | Tenon Medical, Inc. TNON · Entity 2063 | Exercise / conversionCommon Stock | 6,207 | $1.62 | $10,055.34 |
DisclosureSEC source: 0001575872-23-000843 · ownership.xml · nonDerivative · entry 1 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,207 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: These shares of common stock were issued pursuant to the vesting of Restricted Stock Units. F1 · kind: These shares of common stock were issued pursuant to the vesting of Restricted Stock Units. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 16:45 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 463 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-016284 · form4.xml · nonDerivative · entry 1 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,280 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 4,155 restricted stock units. Read SEC document |
| December 30, 2022 Filed Jan 4, 2023 16:36 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 422 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-000251 · doc1.xml · nonDerivative · entry 1 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,817 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 4,155 restricted stock units. Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 17:47 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 359 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-018214 · doc1.xml · nonDerivative · entry 1 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,395 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 4,155 restricted stock units. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 20:31 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 382 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-013692 · doc1.xml · nonDerivative · entry 1 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,036 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 4,155 restricted stock units. Read SEC document |
| June 13, 2022 Filed Jun 22, 2022 01:12 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantStock Option (Right to Buy) · Derivative | 18,253 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0001209191-22-038614 · doc4.xml · derivative · entry 1 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,253 Underlying: Common Stock · 18,253 shares Expires 2032-06-12 F1 · derivative.exercise_date: The shares subject to the option shall vest in twelve (12) equal consecutive monthly installments until all of the option shares are fully vested and exercisable. Read SEC document |
| May 26, 2022 Filed May 27, 2022 21:04 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 4,155 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-011891 · doc1.xml · nonDerivative · entry 1 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,654 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of May 26, 2022 or (ii) the next Annual Meeting following May 26, 2022, subject to the Reporting Person's continued service to the issuer. F2 · balance_after: Includes 4,155 restricted stock units. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 21:54 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 231 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-008044 · doc1.xml · nonDerivative · entry 1 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,499 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 1,167 restricted stock units. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 18:02 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 206 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-000340 · doc1.xml · nonDerivative · entry 1 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,268 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 1,167 restricted stock units. Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 18:32 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 143 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-017863 · doc1.xml · nonDerivative · entry 1 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,062 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 1,167 restricted stock units. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 17:27 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 101 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-012950 · doc1.xml · nonDerivative · entry 1 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,919 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 1,167 restricted stock units. Read SEC document |
| May 25, 2021 Filed May 26, 2021 20:59 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 1,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-011221 · doc1.xml · nonDerivative · entry 1 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,818 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of May 25, 2021 or (ii) the next Annual Meeting following May 25, 2021, subject to the Reporting Person's continued service to the issuer. F2 · balance_after: Includes 1,167 RSUs. Read SEC document |
| April 26, 2021 Filed Apr 26, 2021 21:21 UTC | NeuroPace Inc NPCE · Entity 5459 | ConversionSeries B' Preferred Stock · Derivative | 450,880 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-028335 · doc4.xml · derivative · entry 3 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 450,880 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Each share of Preferred Stock automatically converted on a 1-for-1 basis into Common Stock upon the closing of the Issuer's initial public offering, for no additional consideration. The Preferred Stock has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock automatically converted on a 1-for-1 basis into Common Stock upon the closing of the Issuer's initial public offering, for no additional consideration. The Preferred Stock has no expiration date. Read SEC document |
| April 26, 2021 Filed Apr 26, 2021 21:21 UTC | NeuroPace Inc NPCE · Entity 5459 | ConversionSeries A' Preferred Stock · Derivative | 21,486 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-028335 · doc4.xml · derivative · entry 2 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,486 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Each share of Preferred Stock automatically converted on a 1-for-1 basis into Common Stock upon the closing of the Issuer's initial public offering, for no additional consideration. The Preferred Stock has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock automatically converted on a 1-for-1 basis into Common Stock upon the closing of the Issuer's initial public offering, for no additional consideration. The Preferred Stock has no expiration date. Read SEC document |
| April 26, 2021 Filed Apr 26, 2021 21:21 UTC | NeuroPace Inc NPCE · Entity 5459 | ConversionCommon Stock | 472,366 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-028335 · doc4.xml · nonDerivative · entry 1 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 565,657 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 21, 2021 Filed Apr 23, 2021 23:43 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantStock Option (Right to Buy) · Derivative | 21,698 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-21-028191 · doc4.xml · derivative · entry 2 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,698 Underlying: Common Stock · 21,698 shares Expires 2031-04-20 F2 · derivative.exercise_date: 1/36th of the shares subject to the option vest in equal monthly installments commencing May 21, 2021. Read SEC document |
| April 21, 2021 Filed Apr 23, 2021 23:43 UTC | NeuroPace Inc NPCE · Entity 5459 | PurchaseCommon Stock | 50,000 | $17.00 | $850,000.00 |
DisclosureSEC source: 0001209191-21-028191 · doc4.xml · nonDerivative · entry 1 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,291 F1 · shares: Reflects shares purchased from the underwriters in the Companys initial public offering. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 16:56 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 120 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-007528 · doc1.xml · nonDerivative · entry 1 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,651 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 1,376 restricted stock units. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 17:23 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 96 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-000321 · doc1.xml · nonDerivative · entry 1 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,531 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 1,376 restricted stock units. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 16:55 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 120 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-017493 · doc1.xml · nonDerivative · entry 1 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,435 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 1,376 restricted stock units. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 18:48 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 70 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-012889 · doc1.xml · nonDerivative · entry 1 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,315 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 1,376 restricted stock units. Read SEC document |
| May 21, 2020 Filed May 26, 2020 14:29 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 1,376 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-011145 · doc1.xml · nonDerivative · entry 1 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,245 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of May 21, 2020 or (ii) the next Annual Meeting following May 21, 2020, subject to the Reporting Person's continued service to the issuer. F2 · balance_after: Includes 1,376 restricted stock units. Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 16:39 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 167 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-007439 · doc1.xml · nonDerivative · entry 1 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,869 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 2,913 restricted stock units. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 16:16 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 142 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-000328 · doc1.xml · nonDerivative · entry 1 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,702 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 2,913 restricted stock units. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 21:53 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 194 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-019158 · doc1.xml · nonDerivative · entry 1 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,560 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 2,913 restricted stock units. Read SEC document |
| May 20, 2019 Filed May 22, 2019 17:58 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 2,913 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-011868 · doc1.xml · nonDerivative · entry 1 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,366 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of May 20, 2019 or (ii) the next Annual Meeting following May 20, 2019, subject to the Reporting Person's continued service to the issuer. F2 · balance_after: Includes 2,913 RSUs. Read SEC document |
| May 21, 2018 Filed May 23, 2018 19:17 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 3,785 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-025421 · doc1.xml · nonDerivative · entry 1 Fischer Frank M · CIK 0001297260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,453 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of May 21, 2018 or (ii) the next Annual Meeting following May 21, 2018, subject to the Reporting Person's continued service to the issuer. F2 · balance_after: Includes 3,785 RSUs. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.